ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.599,57
-0,46%
S&P 500
5.222,68
0,16%
US Dollar vs BRL
5,1568
0,00%
Bitcoin
61.177,14
0,63%
Brent Oil
82,585
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Nektar Therapeutics (NKTR)

  7. Nektar Therapeutics (NKTR) Notícias

NKTR

Nektar Therapeutics (NKTR)

Nektar Therapeutics
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NKTR
DataHoraFonteTítuloCódigoCompanhia
09/05/202417:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
09/05/202417:15PR Newswire (US)Nektar Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:NKTRNektar Therapeutics
02/05/202419:00PR Newswire (US)Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
22/03/202415:00PR Newswire (US)Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceNASDAQ:NKTRNektar Therapeutics
05/03/202419:11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NKTRNektar Therapeutics
05/03/202411:00PR Newswire (US)Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia AreataNASDAQ:NKTRNektar Therapeutics
04/03/202418:15PR Newswire (US)Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial ResultsNASDAQ:NKTRNektar Therapeutics
04/03/202410:30PR Newswire (US)Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGXNASDAQ:NKTRNektar Therapeutics
27/02/202420:00PR Newswire (US)Nektar Management to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:NKTRNektar Therapeutics
26/02/202420:00PR Newswire (US)Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
22/02/202422:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
20/02/202417:55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
14/02/202419:03Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NKTRNektar Therapeutics
03/01/202420:00PR Newswire (US)Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CANASDAQ:NKTRNektar Therapeutics
11/12/202320:00PR Newswire (US)Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:NKTRNektar Therapeutics
07/11/202318:15PR Newswire (US)Nektar Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:NKTRNektar Therapeutics
31/10/202319:00PR Newswire (US)Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
13/10/202309:30PR Newswire (US)Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV CongressNASDAQ:NKTRNektar Therapeutics
02/10/202310:00PR Newswire (US)Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell TherapyNASDAQ:NKTRNektar Therapeutics
27/09/202310:00PR Newswire (US)Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung CancerNASDAQ:NKTRNektar Therapeutics
13/09/202310:00PR Newswire (US)Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisNASDAQ:NKTRNektar Therapeutics
06/09/202319:00PR Newswire (US)Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13thNASDAQ:NKTRNektar Therapeutics
17/08/202317:30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NKTRNektar Therapeutics
11/08/202322:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NKTRNektar Therapeutics
08/08/202317:15PR Newswire (US)Nektar Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:NKTRNektar Therapeutics
07/08/202307:30PR Newswire (US)Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & CompanyNASDAQ:NKTRNektar Therapeutics
01/08/202319:00PR Newswire (US)Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
23/06/202307:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NKTRNektar Therapeutics
15/06/202319:27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NKTRNektar Therapeutics
14/06/202318:16Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:NKTRNektar Therapeutics
 Apresentando as notícias mais relevantes sobre:NASDAQ:NKTR

Seu Histórico Recente

NASDAQ
RFDI
First Trust RiverFront D...
COIN
RENAUST
Warena Token
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados